Glutathione Peroxidase 4/GPX4 Antibody

Immunohistochemistry: Glutathione Peroxidase 4/GPX4 Antibody [NBP2-54979] -

Immunohistochemistry: Glutathione Peroxidase 4/GPX4 Antibody [NBP2-54979] - Cyst(e)ine promotes Glutathione Peroxidase 4/GPX4 protein synthesis partly through Rag-mTORC1-4EBP signaling. l) Representative images from immunohistochemical staining of kidney tumor tissue microarray for Glutathione Peroxidase 4/GPX4 and P-4EBP1. m) Summary and statistical analysis of immunohistochemical staining results for Glutathione Peroxidase 4/GPX4 and P-4EBP1 in tumor tissue microarray. Tissue microarray analysis revealed that P-4EBP1 staining correlated with Glutathione Peroxidase 4/GPX4 level. Image collected and cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/33707434/) licensed under a CC-BY license.

Immunohistochemistry: Glutathione Peroxidase 4/GPX4 Antibody [NBP2-54979] -

Immunohistochemistry: Glutathione Peroxidase 4/GPX4 Antibody [NBP2-54979] - Cyst(e)ine promotes GPX4 protein synthesis partly through Rag-mTORC1-4EBP signaling. i WB analysis of protein expression in control (sgCon) & 4EBP1/2-double-knockout (DKO-1 & DKO-2) UMRC6 cells. Image collected & cropped by CiteAb from following publication (https://pubmed.ncbi.nlm.nih.gov/33707434), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Immunohistochemistry: Glutathione Peroxidase 4/GPX4 Antibody [NBP2-54979] -

Immunohistochemistry: Glutathione Peroxidase 4/GPX4 Antibody [NBP2-54979] - mTORC1 inhibition sensitizes cancer cells or tumors to ferroptosis.a UMRC6 cells were treated with 1 μM RSL3 (or 1 μM ML162), or 1 μM Torin1, or both combined with or without 5 μM Ferrostatin-1 (Ferr-1) or 100 μM deferoxamine (DFO) for 6 h. Then lipid peroxidation was assessed using BODIPY™ 581/591 C11 staining followed by FACS analysis. b Bar graph showing the viability of UMRC6 cells treated with drugs using indicated combination. Concentration of each drug is described as follows. RSL3, 1 μM; ML162, 1 μM; Torin1, 1 μM; Ferr-1, 5 μM; DFO, 100 μM. n = 3. c Bar graph showing the viability of indicated cells treated with 300 nM RSL3, or 1 μM Torin1, or both for 8 h. n = 5. d Bar graph showing the viability of indicated cells treated with 300 nM ML162, or 1 μM Torin1, or both for 8 h. n = 5. e Bar graph showing the viability of indicated cells treated with different concentrations of cystine for 48 h. n = 4. f Plot showing the viability of indicated cells treated with different concentrations of erastin for 36 h. n = 4. g Volumes of PDX tumors in mice treated daily with 30 mg/kg IKE, or 10 mg/kg AZD8055, or both at different time points as shown. n = 5 mice per group. h Percentages of P-4EBP1-, GPX4-, or 4-HNE-positive stained cells per field. n = 5 randomly selected high-power fields per group. i Haematoxylin & eosin & immunohistochemical staining of PDX tumor samples collected from mice at the end of treatments described in g. For all panels, error bars are mean ± SD. If not otherwise specified, n indicates biologically independent repeats. P value was determined by two-tailed unpaired Student’s t test. For f & g, p value was determined by two-way ANOVA test. Source data are provided as a Source Data file. Image collected & cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/33707434), licensed under a CC-BY license. Not internally tested by Novus Biologicals.